Evidence map›Paper›PMID 35712073›Full record

ArticleiScience2022

Poroptosis: A form of cell death depending on plasma membrane nanopores formation.

Hao Li, Zihao Wang, Xiaocui Fang, Wenfeng Zeng, Yanlian Yang, Lingtao Jin, Xiuli Wei, Yan Qin, Chen Wang, Wei Liang

Open access · goldAbstract read
In one paragraph

Article in iScience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Growth inhibitory effect ofJournal of advanced veterinary and animal research · 2024
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Hao LiProtein & Peptide Pharmaceutical Laboratory, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, P. R. China.
Zihao WangProtein & Peptide Pharmaceutical Laboratory, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, P. R. China.
Xiaocui FangKey Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, and Key Laboratory of Standardization and Measurement for Nanotechnology, National Center for Nanoscience and Technology, Chinese Academy of Sciences, Beijing 100190, P. R. China.
Wenfeng ZengProtein & Peptide Pharmaceutical Laboratory, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, P. R. China.
Yanlian YangKey Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, and Key Laboratory of Standardization and Measurement for Nanotechnology, National Center for Nanoscience and Technology, Chinese Academy of Sciences, Beijing 100190, P. R. China.
Lingtao JinDepartment of Molecular Medicine, UT Health San Antonio, San Antonio, TX 78229, USA.
Xiuli WeiProtein & Peptide Pharmaceutical Laboratory, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, P. R. China.
Yan QinProtein & Peptide Pharmaceutical Laboratory, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, P. R. China.
Chen WangKey Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, and Key Laboratory of Standardization and Measurement for Nanotechnology, National Center for Nanoscience and Technology, Chinese Academy of Sciences, Beijing 100190, P. R. China.
Wei LiangProtein & Peptide Pharmaceutical Laboratory, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, P. R. China.
Chinese Academy of Sciences · CNThe University of Texas Health Science Center at San Antonio · US

Funding

The role of NFIB-MAST1 signaling in mediating adaptive cisplatin resistance in SCLCR37CA249305 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Lingtao Jin · 2020 to 2026
$2.9M
Novel protein kinase signaling associated with platinum resistance in ovarian cancerR01CA256482 · NCI · UNIVERSITY OF FLORIDA · PI HUANG, SHUANG, SONG, LINA · 2021 to 2025
$2.2M
NCI NIH HHS R01 CA256482NCI NIH HHS R37 CA249305
6 · The paper itself

Abstract

Immunogenic cell death (ICD) in malignant cells can decrease tumor burden and activate antitumor immune response to obtain lasting antitumor immunity, leading to the elimination of distant metastases and prevention of recurrence. Here, we reveal that ppM1 peptide is capable of forming irreparable transmembrane pores on tumor cell membrane, leading to ICD which we name poroptosis. Poroptosis is directly dependent on cell membrane nanopores regardless of the upstream signaling of cell death. ppM1-induced poroptosis was characterized by the sustained release of intracellular LDH. This unique feature is distinct from other well-characterized types of acute necrosis induced by freezing-thawing (F/T) and detergents, which leads to the burst release of intracellular LDH. Our results suggested that steady transmembrane-nanopore-mediated subacute cell death played a vital role in subsequent activated immunity that transforms to an antitumor immune microenvironment. Selectively generating poroptosis in cancer cell could be a promise strategy for cancer therapy.

Indexed as

CancerCell biologyFunctional aspects of cell biology

Identifiers

PMID35712073
PMCPMC9194171
OpenAlexW4281713629

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.